This site requires flash 8 You currently do not have the necessary Macromedia Flash plug-in to view this page
Click here to download the Macromedia Flash plug-in
Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (desamino cysteinyl) residue. Eptifibatide is indicated for acute coronary syndrome with or without percutaneous coronary intervention and for percutaneous coronary intervention as IV injections. The Eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. Eptifibatide marketed worldwide by GSK and Shering -Plough under the brand name of INTEGRILIN®. INTEGRILIN® Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains either 0.75 mg/mL or 2 mg/mL of eptifibatide. This peptide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, it inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet.
General data on Eptifibatide Active Pharmaceutical Ingredient
Molecular Formula: C35H49N11O9S2 Molecular Weight:832.0 CAS Registry: 148031-34-9;157630-07-4 ATC:B01AC16
TAPI's Eptifibatide Active Pharmaceutical Ingredient
TAPI's Eptifibatide Active Pharmaceutical Ingredient is produced in Assia Industries Limited –Teva Tech site in Beer Sheva, Israel.
Over the last 15 years TAPI has developed the expertise in developing and commercialization of peptide Active pharmaceutical ingredients. With numerous worldwide approvals, we are continuously driven by the goal of helping our customers achieve success-and ultimately approval for their peptide APIs. We offer gr. to hundred Kg. production capabilities, comprehensive technology platform including solid phase, solution phase, and hybrid approach, combined with a well established scientific experience, enabling the implementation of efficient process aimed for high quality product. We offer Custom Synthesis and Manufacturing services on these Active pharmaceutical ingredients.
TAPI provide full service on Eptifibatide and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on this active pharmaceutical ingredient. Contact us today for further inquiries and samples availability information for TAPI's Eptifibatide.
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).
*TAPI stands for Teva's Active Pharmaceutical Ingredients
